180 Life Sciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for 180 Life Sciences Corp from these most-recent analyst ratings.
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/09/2022 | Buy Now | — | Maxim Group | Naz Rahman28% | — | Downgrade | Buy → Hold | Get Alert |
The latest price target for 180 Life Sciences (NASDAQ:ATNF) was reported by Maxim Group on May 9, 2022. The analyst firm set a price target for $0.00 expecting ATNF to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for 180 Life Sciences (NASDAQ:ATNF) was provided by Maxim Group, and 180 Life Sciences downgraded their hold rating.
There is no last upgrade for 180 Life Sciences
The last downgrade for 180 Life Sciences Corp happened on May 9, 2022 when Maxim Group changed their price target from N/A to N/A for 180 Life Sciences Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 180 Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 180 Life Sciences was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.
While ratings are subjective and will change, the latest 180 Life Sciences (ATNF) rating was a downgraded with a price target of $0.00 to $0.00. The current price 180 Life Sciences (ATNF) is trading at is $1.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.